Biomerica, Inc.

Biomerica, Inc. is a global biomedical technology company that develops, patents, manufactures, and markets advanced in-vitro diagnostic (IVD) solutions and therapeutic products. Headquartered in Irvine, California, the company's mission is to improve the quality of life by developing and delivering well-designed and high-performing diagnostic products. Their vision is to be a leader in the development of diagnostic-guided therapies that will revolutionize care for patients suffering from Irritable Bowel Syndrome (IBS) and other inflammatory diseases.

The company's key product focus is on gastrointestinal and inflammatory diseases, food intolerances, diabetes, and other medical conditions. Their diagnostic test kits analyze blood, urine, nasal, or fecal samples for various diagnoses. A flagship product, inFoods® IBS, is designed to identify patient-specific foods that, when eliminated from the diet, may alleviate IBS symptoms. Biomerica's solutions are designed for clinical laboratories, point-of-care settings, and at-home use, and the company also offers contract manufacturing services.

Zackary S. Irani serves as the CEO and Chairman of the Board. In recent news, Biomerica's inFoods® IBS data was accepted for presentation at Digestive Disease Week 2026. The company also announced that the Centers for Medicare & Medicaid Services (CMS) set a national Medicare payment rate of $300 for the inFoods® IBS test, effective January 1, 2026, following a Medicare Administrative Contractor's confirmation of individual claim review. Biomerica has launched inFoods® IBS in Canada through strategic partnerships and received its first commercial order for the H. pylori test (hp+detect) from a major European clinical laboratory chain. Additionally, Vietnam approved Biomerica's EZ Detect™ for nationwide distribution, and the company reported real-world data demonstrating significant pain and bloating reduction with the inFoods® IBS therapy. In April 2025, Biomerica implemented a 1-for-8 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Latest updates

Biomerica IBS Data Presentation Signals Validation of Personalized Dietary Approach

Event summary

  • Biomerica’s inFoods® IBS diagnostic-guided therapy data will be presented as a poster at Digestive Disease Week 2026 (May 2–5) in Chicago.
  • The study, conducted by researchers from the University of Michigan and Cleveland Clinic, evaluates the real-world clinical effectiveness of the inFoods® IBS therapy.
  • The presentation builds on a 2025 Gastroenterology study showing 59.6% of patients using the therapy achieved FDA endpoints for abdominal pain reduction, compared to 42.1% in the control group.
  • inFoods® IBS uses a finger-stick blood test to identify patient-specific food triggers for IBS symptoms.

The big picture

Biomerica's inFoods® IBS therapy represents a shift towards personalized, non-pharmacological treatments for Irritable Bowel Syndrome, a condition affecting an estimated 30-45 million adults in the US and representing a $30 billion addressable market. The acceptance of the study data for presentation at DDW, a major gastroenterology conference, validates the company’s approach and signals growing interest in precision dietary management. However, the company's success depends on broader clinical adoption and favorable reimbursement policies.

What we're watching

Clinical Adoption
The presentation's reception and subsequent physician adoption of the inFoods® IBS test will be crucial for driving revenue growth, as the therapy's success hinges on integration into clinical workflows.
Reimbursement
Whether insurance providers will cover the inFoods® IBS test remains a key uncertainty, potentially limiting accessibility and market penetration despite demonstrated efficacy.
Competitive Landscape
The emergence of competing diagnostic or therapeutic approaches for IBS management could erode Biomerica’s market share, necessitating continued innovation and differentiation.
CID: 1449